Related Experiment Videos
In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and
Thomas J Lang1, Phuong Nguyen, Robert Peach
1Research Service, Baltimore Veterans Affairs Medical Center, and Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|April 9, 2002
Summary
This study reveals distinct roles for CD80 and CD86 in T cell activation. CD86 is crucial for naive CD4(+) T cell activation, while CD80 plays a key role in regulating Th1 responses and CD8(+) T cell activation via CTLA-4.
Area of Science:
- Immunology
- T cell biology
Background:
- CD80 and CD86 are co-stimulatory molecules essential for T cell activation.
- Their specific roles in vivo, particularly in the context of T cell differentiation and immune responses, remain incompletely understood.
Purpose of the Study:
- To investigate the functional dichotomy between CD80 and CD86 in naive T cell activation in vivo.
- To elucidate the distinct roles of CD80 and CD86 in mediating graft-versus-host disease (GVHD).
Main Methods:
- Utilized a parent-into-F(1) mouse model of GVHD.
- Administered anti-CD80 or anti-CD86 blocking monoclonal antibodies (mAbs) alone or in combination.
- Assessed T cell activation, maturation, cytokine production, and GVHD outcomes.
Main Results:
- Combined CD80/CD86 blockade abrogated both acute and chronic GVHD by inhibiting CD4(+) T cell activation and maturation.
- Selective CD86 blockade partially inhibited CD4(+) T cell responses.
- Selective CD80 blockade converted chronic GVHD to acute GVHD, associated with enhanced Th1 responses and CD8(+) T cell activation.
Conclusions:
- CD86 is critical for the activation of naive CD4(+) T cells in both Th1 and Th2 responses.
- CD80 is a critical ligand for CTLA-4, mediating the down-regulation of Th1 responses and CD8(+) T cell activation.
- These findings highlight distinct functional roles for CD80 and CD86 in adaptive immunity.